Annexon Inc
ANNXHealthcare|Biotechnology|USA
$5.79
-0.14 (-2.36%)
Tangible Book
$1.26
Earnings Power
$0.88
Upcoming Data Readouts (2)
Oct 2026
Est. completion
P3Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816n=659
Dec 2026
Est. completion
P3Guillain-Barre Syndrome
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
NCT07020819n=30